<DOC>
	<DOCNO>NCT00564720</DOCNO>
	<brief_summary>This randomized phase II trial compare efficacy toxicity Gemcitabine plus Erlotinib versus Gemcitabine plus Erlotinib plus Oxaliplatin patient pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin , Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically confirm pancreatic cancer . Measurable disease . Absence ascites obstructive jaundice . ECOG Performance Status 02 . Adequate liver kidney bone marrow function . Written informed consent . Chronic diarrheic syndrome . Uncontrolled brain metastasis radiation . Liver infiltration 50 % . Peripheral neuropathy â‰¥ 2 . No second primary malignancy within past 5 year , except nonmelanomas skin cancer situ carcinoma cervix . No active uncontrolled infection . Active cardiac disease : unstable angina onset angina within last 3 month , myocardial infarction within 6 month , congestive heart failure &gt; class II , cardiac ventricular arrhythmia require antiarrhythmic therapy . Women pregnant lactating .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>